Literature DB >> 31142482

Novel HMGA2-YAP1 fusion gene in aggressive angiomyxoma.

Mee-Young Lee1, Brandon da Silva2, Daniel C Ramirez3,4, Robert G Maki1,5.   

Abstract

We describe a case of a 44-year-old woman with locally advanced aggressive angiomyxoma with a novel translocation high-mobility group AT-hook 2-yes-associated protein 1 (HMGA2-YAP1) fusion, implying a t(11;12)(q22.1;q14.3) translocation. She was started on gonadotropin-releasing hormone agonist injection and an aromatase inhibitor for persistent disease, which responded to treatment; she was subsequently treated with radiation before a more definitive operation was conducted. This case report indicates that HGMA2-YAP1-translocated aggressive angiomyxoma is responsive to oestrogen antagonism and hopefully will allow for the development of diagnostics useful for this rare but often morbid neoplasm. This case also highlights the importance of appropriate workup of a soft tissue mass. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gynecological cancer; therapeutic indications

Mesh:

Substances:

Year:  2019        PMID: 31142482      PMCID: PMC6557357          DOI: 10.1136/bcr-2018-227475

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery.

Authors:  I J M Han-Geurts; A N van Geel; L van Doorn; A M M Eggermont; C Verhoef
Journal:  Eur J Surg Oncol       Date:  2006-07-25       Impact factor: 4.424

2.  Treatment of aggressive angiomyxoma of the female perineum: Combined operative and hormone therapy.

Authors:  Sun-Wha Im; Seung Su Han
Journal:  J Obstet Gynaecol       Date:  2016-05-05       Impact factor: 1.246

3.  Deregulation of HMGA2 in an aggressive angiomyxoma with t(11;12)(q23;q15).

Authors:  Francesca Micci; Ioannis Panagopoulos; Bodil Bjerkehagen; Sverre Heim
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

4.  Aggressive angiomyxoma of the vulva: A case report.

Authors:  Kyoung-A Lee; Jung-Won Seo; Na-Ra Yoon; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  Obstet Gynecol Sci       Date:  2014-03-15

5.  Aggressive angiomyxoma of the vulva: Dramatic response to gonadotropin-releasing hormone agonist therapy.

Authors:  W G McCluggage; T Jamieson; S P Dobbs; A Grey
Journal:  Gynecol Oncol       Date:  2005-10-21       Impact factor: 5.482

6.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

7.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.

Authors:  Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Robert A Soslow; Mario M Leitao; Carol Aghajanian; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2009-11-24       Impact factor: 5.482

Review 9.  HMGA2 and high-grade serous ovarian carcinoma.

Authors:  Jingjing Wu; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

10.  Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain.

Authors:  M Sudol; P Bork; A Einbond; K Kastury; T Druck; M Negrini; K Huebner; D Lehman
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

View more
  5 in total

1.  Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Marius Lund-Iversen; Ingvild Lobmaier; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Fusion of High Mobility Group AT-hook 2 Gene (HMGA2) With the Chromosome 12 Open Reading Frame 42 Gene (C12orf42) in an Aggressive Angiomyxoma With del(12)(q14q23) as the Sole Cytogenetic Anomaly.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Ingvild Lobmaier; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

3.  Decreased PTGDS Expression Predicting Poor Survival of Endometrial Cancer by Integrating Weighted Gene Co-Expression Network Analysis and Immunohistochemical Validation.

Authors:  Ruoyao Zou; Mingjun Zheng; Mingzi Tan; Haoya Xu; Nannan Luan; Liancheng Zhu
Journal:  Cancer Manag Res       Date:  2020-06-26       Impact factor: 3.989

4.  WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma.

Authors:  Jordan H Driskill; Yonggang Zheng; Bo-Kuan Wu; Li Wang; Jing Cai; Dinesh Rakheja; Michael Dellinger; Duojia Pan
Journal:  Genes Dev       Date:  2021-03-25       Impact factor: 11.361

5.  Long non-coding RNA HIT000218960 is associated with poor prognosis in patients with gastric cancer.

Authors:  Kunbo Dong; Li Bai; Deyong Tong; Xiuna Shi; Sirong Wei; Yongguo Cai
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.